New hope for tough esophageal cancer: experimental drug takes on chemo
NCT ID NCT06304974
First seen Nov 17, 2025 · Last updated May 14, 2026 · Updated 26 times
Summary
This phase 3 study tests a new drug called BL-B01D1 against standard chemotherapy for people with advanced esophageal cancer that has worsened after initial treatment. About 497 participants will be randomly assigned to receive either BL-B01D1 or a doctor-chosen chemo. The goal is to see if the new drug can slow cancer growth and extend survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.